Physician profile
John Kailath
NPI 1619943313
$7,816.96
in general payments reported to CMS, 2019-2025
47 companies · $541 in 2025
The $541 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $218 · 2021: $2,030 · 2022: $1,876 · 2023: $1,147 · 2024: $1,186 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,291 · Education: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.51 |
| Education | $583.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Oncology Corporate, INC. | $841.88 | 2022 | |
| Pfizer INC. | $841.53 | 2019-2025 | |
| Astellas Pharma US INC | $600.48 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Janssen Biotech, INC. | $574.32 | 2019-2023 | Darzalex, Imbruvica, Rybrevant |
| Amgen INC. | $521.53 | 2019-2025 | Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $517.29 | 2019-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $374.25 | 2019-2025 | |
| Seagen INC. | $289.02 | 2021-2023 | |
| Glaxosmithkline, LLC. | $248.54 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Genentech USA, INC. | $233.06 | 2019-2024 | Tecentriq, Alecensa |
| Kite Pharma, INC. | $193.25 | 2020-2023 | Yescarta |
| Abbvie INC. | $188.06 | 2019-2024 | |
| Tempus Ai, INC | $160.99 | 2024 | Xt Cdx |
| Tersera Therapeutics LLC | $151.55 | 2021-2023 | Zoladex |
| Pharmacyclics LLC, An Abbvie Company | $146.33 | 2021-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kailath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.